Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadastuximab talirine versus placebo with azacitidine or decitabine in older adults with newly diagnosed AML
NL-OMON45635Phase 3Withdrawn
- Sponsor
- Seagen Inc.
- Start
- Nov 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vadastuximab talirine in acute myeloid leukemia (AML) (2 arms), sponsored by Seagen Inc. Primary endpoints: Composite complete remission rate and Overall survival. Planned start Nov 2016; status: withdrawn.
02
Drugs
vadastuximab talirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON45635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45635.